NBN and metabolic dysfunction-associated steatotic liver disease: Our data are consistent with previous studies that FTZ has a hypolipidemic effect under metabolic stress conditions, and its therapeutic effect is similar to that of ATV, which is recommended for NAFLD treatment in several national clinical guidelines, including the United States, and can effectively reduce lipid deposition and lipotoxicity caused by HFD (37–39).